HutchMED (China) LIMITED (HMDCF) Return on equity 2016–2025
HutchMED (China) LIMITED (HMDCF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
36.9%FY2025 · since FY2016: 6.3% → 36.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 36.9% | +31.9 pp |
| FY2024 | 5.0% | -8.8 pp |
| FY2023 | 13.8% | +72.9 pp |
| FY2022 | -59.1% | -39.4 pp |
| FY2021 | -19.7% | +6.2 pp |
| FY2020 | -26.0% | +10.8 pp |
| FY2019 | -36.8% | -17.6 pp |
| FY2018 | -19.2% | -13.4 pp |
| FY2017 | -5.8% | -12.1 pp |
| FY2016 | 6.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More HMDCF financial trends
HMDCF RevenueHMDCF Net incomeHMDCF Net marginHMDCF Gross profitHMDCF Gross marginHMDCF Operating incomeHMDCF Operating marginHMDCF Operating cash flowHMDCF Free cash flowHMDCF Capital expendituresHMDCF Stock buybacksHMDCF Dividends paidHMDCF Total assetsHMDCF Total liabilitiesHMDCF Shareholders’ equityHMDCF overview →